CIK 0001850270
- Emerging growth company
PROKIDNEY CORP.
Sign in to watch- Ticker
- PROK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- Operating
- EIN
- 981586514
- Phone
- +1 336-999-7028
- Business address
- 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM, NC, 27103
- Former names
- Social Capital Suvretta Holdings Corp. III
- 4 Conversion Director acquired 757,162 shares (conversion)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Regulatory Officer sold 16,412 shares at $2.50 ($41,030)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Conversion Chief Legal Officer acquired 81,928 shares (conversion)
- 4 Planned sale Chief Regulatory Officer sold 826 shares at $2.50 ($2,065)
- 4 Open-market buy 10% owner bought 8,264,462 shares at $2.42 ($19,999,998)
- 4 Planned sale Chief Regulatory Officer sold 17,238 shares at $2.82 ($48,616)
- 4 Open-market buy Director bought 22,617,909 shares at $2.42 ($54,735,340)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Regulatory Officer sold 17,238 shares at $4.08 ($70,386)
- 4 Open-market buy 10% owner bought 177,000 shares at an average $1.42 ($251,666)
- 4 Planned sale SVP of Regulatory Development sold 17,238 shares at an average $2.51 ($43,343)
Page 3 of 8 · 153 filings